NovoRapid® / NovoLog®
Insulin Aspart is a rapid-acting insulin analog for mealtime blood glucose control. Faster onset and shorter duration than regular human insulin.
| Dosage Form | SC Injectable (Prefilled Pen / Vial / Cartridge) |
| Strength | 100 units/mL |
| Storage | Store at 2–8°C. After first use, store at room temperature for up to 28 days. |
| Category | Diabetes & GLP-1 |
| Availability | Available for Transfer |
Type 1 and type 2 diabetes mellitus (prandial insulin for mealtime glycemic control).
Rapid-acting insulin analog where proline at B28 is replaced by aspartic acid, reducing self-association and enabling faster absorption after subcutaneous injection.
Each Burrard Pharmaceuticals technology transfer package for Insulin Aspart includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.